Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myrtenal is a bicyclic monoterpenoid, naturally present in the essential oils of diverse plants, including *Myrtus communis*, rosemary, spearmint, peppermint, mandarin peel, and more. It is a small molecule characterized by the formula C10H14O. While not an approved pharmaceutical, studies report diverse experimental biological activities including antihyperglycemic, antioxidant, antitumor, analgesic, anti-inflammatory, neuroprotective, vasodilatory, and antibacterial effects. Myrtenal acts through multiple mechanisms, including modulation of glucose metabolism, antioxidant activity, regulation of neurotransmitters, inhibition of V-type ATPase on tumor cells, anti-inflammatory activity (through suppression of IL-1β, TNF-α, and NLRP3 inflammasome), and influencing monoamines in the CNS. It is investigated mostly in preclinical settings in animal models for diabetes, cancer, neurodegenerative disorders (Parkinson’s disease, dementia), and as an analgesic and anti-inflammatory agent. Myrtenal is also a minor component in some foods and a precursor in pinene metabolism in plants[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on myrtenal.